Integra Lifesciences Holdings Corp Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $1.6B+2.3% YoYTTM through 30 Jun 2026
Net Income -$7.2MTTM through 30 Jun 2026
Free Cash Flow $25.8MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 50.9% |
| EBITDA Margin | 10.7% |
| Operating Margin | -30.2% |
| Net Margin | -0.4% |
Returns
-0.5%ROE
-0.1%ROA
-0.5%ROIC
Balance Sheet Health
Debt / Equity1.78x
Current Ratio3.60x
Net Debt$1.6B
Cash & Equivalents$214.4M
Quality Metrics
Altman Z-Score1.28
Piotroski F-Score5 / 9
FCF Margin1.6%
Rule of 403.2
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $1.6B
Diluted EPS-$0.09TTMFY2025: $-6.74
Dividend
No dividend
Capital Allocation
Capex Intensity3.6%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Codman Specialty Surgical | $1.2B | +5.0% | |
| Tissue Technologies | $434.7M | -7.0% |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.